Redeye’s valuation of Vicore is under review with a positive bias following data from the phase II trial with C21 in Covid-19 patients. Today, Vicore released an expanded data analysis from the trial which strengthens our view of the results. We are particularly encouraged by the oxygen endpoint, which showed that one patient in the C21 group compared to 11 patients in the placebo group needed oxygen supplementation at the end of the trial (p<0.002). We will elaborate more on the complete dataset in a subsequent update.